CDR505 / CDR-Life - LARVOL DELTA

A novel T cell engager antibody for the treatment of HLA-A*01/KK-LC-1-positive tumors (AACR 2025) - "Here, we describe CDR505, a novel antibody-based T cell engager (TCE) for the treatment of KK-LC-1-expressing solid tumors...It shows high specificity for KK-LC-1/HLA-A*01 and shows an overall safe profile in the presence of normal human cells. Future studies will include in vivo efficacy testing and a broader range of cellular assays using tissues and cultured cells as part of the preclinical studies that will be included in the IND application."

Gastric Cancer • Lung Cancer • Oncology • Solid Tumor • CD69 • GZMB • HLA-A • IFNG • IL2 • IL2RA • IL6 • TNFA

Second T Cell Engager for KK-LC-1-Positive Tumors (Abstract #3493) (Businesswire) - "Key findings for CDR505 included: Potent and Selective: CDR505 demonstrated potent and selective killing of KK-LC-1-positive cancer cells; Preferential T Cell Activation: The molecule showed preferential activation of CD8+ T cells, confirming the intended mechanism of action. High Target Specificity: CDR505 exhibited high specificity for the KK-LC-1 peptide/HLA-A*01:01 complex, demonstrating low risk for off-target binding; Desirable Pharmaceutical Properties: The molecule demonstrated excellent manufacturability, solubility and stability characteristics, supporting its feasibility for subcutaneous formulation."

Preclinical • Lung Cancer

CDR-Life Announces Pipeline Expansion of Highly Tumor-Targeted T Cell Engagers (Businesswire) - "CDR-Life Inc. today announced an expansion of its pipeline of novel T cell engagers (TCE) with the addition of CDR813 and CDR505. CDR813 is a highly potent and selective TCE candidate targeting tumors expressing PRAME (preferentially expressed antigen in melanoma) in HLA-A*02:01 patients....While most TCE programs target the HLA-A02 haplotype, CDR505 targets KK-LC-1/HLA-A*01, expanding the potential of TCEs to benefit a large patient population with high unmet need."

New molecule • Melanoma • Oncology • Skin Cancer • Solid Tumor

CDR-Life Unveils Results on T-Cell Engagers Targeting Hard-to-Treat Solid Tumors at AACR 2024 (GlobeNewswire) - "CDR-Life...announced the presentation of preclinical data demonstrating the promising anti-tumor properties of its peptide major histocompatibility complex (pMHC) T-cell engager (TCE) antibodies at the American Association for Cancer Research (AACR) Annual Meeting 2024....The evaluated TCEs demonstrated potent killing of KK-LC-1/HLA-A*01-positive cancer cells. The data showed no evidence for off-target cytotoxic activity towards KK-LC-1-negative/ HLA-A*01-positive healthy human cells. In vitro studies showed significantly higher TCE-dependent T-cell activation towards cells presenting the target peptide compared to the risk peptides."

Preclinical • Oncology • Solid Tumor